Facilitated PCI in patients with ST-elevation myocardial
infarction

J 2008

Facilitated PCI in patients with ST-elevation myocardial infarction

ELLIS, SG, M TENDERA, Belder MA DE, Boven AJ VAN, Petr WIDIMSKÝ et. al.

Basic information

Original name

Facilitated PCI in patients with ST-elevation myocardial infarction

Authors

Edition

New England Journal of Medicine, USA, MASSACHUSETTS MEDICAL SOC, 2008, 0028-4793

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 50.017

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1056/NEJMoa0706816

UT WoS

000256023600003

Změněno: 23/2/2015 15:41, Ing. Mgr. Věra Pospíšilíková

Abstract

V originále

Background We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in patients with acute ST-segment elevation myocardial infarction, as compared with abciximab administered immediately before the procedure (primary PCI). Methods In this international, double-blind, placebo-controlled study, we randomly assigned patients with ST-segment elevation myocardial infarction who presented 6 hours or less after the onset of symptoms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI. All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization. Results A total of 2452 patients were randomly assigned to a treatment group. Significantly more patients had early ST-segment resolution with combination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%; P = 0.01 and P = 0.003, respectively). The primary end point occurred in 9.8%, 10.5%, and 10.7% of the patients in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group, respectively (P = 0.55); 90-day mortality rates were 5.2%, 5.5%, and 4.5%, respectively (P = 0.49). Conclusions Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-segment elevation myocardial infarction.

Citovat

ELLIS, SG, M TENDERA, Belder MA DE, Boven AJ VAN, Petr WIDIMSKÝ, L JANSSENS, HR ANDERSEN, A BETRIU, S SAVONITTO, J ADAMUS, JZ PERUGA, M KOSMIDER, O KATZ, T NEUNTEUFL, J JORGOVA, M DOROBANTU, L GRINFELD, P ARMSTRONG, BR BRODIE, HC HERRMANN, G MONTALESCOT, FJ NEUMANN, MB EFFRON, ES BARNATHAN and EJ TOPOL. Facilitated PCI in patients with ST-elevation myocardial infarction. New England Journal of Medicine. USA: MASSACHUSETTS MEDICAL SOC, 2008, vol. 358, No 21, p. 2205-2217. ISSN 0028-4793. Available from: https://dx.doi.org/10.1056/NEJMoa0706816.

@article{1227630,
   author = {Ellis, SG and Tendera, M and de, Belder MA and van, Boven AJ and Widimský, Petr and Janssens, L and Andersen, HR and Betriu, A and Savonitto, S and Adamus, J and Peruga, JZ and Kosmider, M and Katz, O and Neunteufl, T and Jorgova, J and Dorobantu, M and Grinfeld, L and Armstrong, P and Brodie, BR and Herrmann, HC and Montalescot, G and Neumann, FJ and Effron, MB and Barnathan, ES and Topol, EJ and Siegelová, Jarmila},
   article_location = {USA},
   article_number = {21},
   doi = {http://dx.doi.org/10.1056/NEJMoa0706816},
   language = {eng},
   issn = {0028-4793},
   journal = {New England Journal of Medicine},
   note = {Paní prof. Siegelová vyjmenována jako jedna z "Investigators" z ČR. Do is.muni zaevidováno na základě žádosti pana prof. Dobšáka.},
   title = {Facilitated PCI in patients with ST-elevation myocardial infarction},
   volume = {358},
   year = {2008}
}

TY  - JOUR
ID  - 1227630
AU  - Ellis, SG - Tendera, M - de, Belder MA - van, Boven AJ - Widimský, Petr - Janssens, L - Andersen, HR - Betriu, A - Savonitto, S - Adamus, J - Peruga, JZ - Kosmider, M - Katz, O - Neunteufl, T - Jorgova, J - Dorobantu, M - Grinfeld, L - Armstrong, P - Brodie, BR - Herrmann, HC - Montalescot, G - Neumann, FJ - Effron, MB - Barnathan, ES - Topol, EJ - Siegelová, Jarmila
PY  - 2008
TI  - Facilitated PCI in patients with ST-elevation myocardial infarction
JF  - New England Journal of Medicine
VL  - 358
IS  - 21
SP  - 2205-2217
EP  - 2205-2217
PB  - MASSACHUSETTS MEDICAL SOC
SN  - 00284793
N1  - Paní prof. Siegelová vyjmenována jako jedna z "Investigators" z ČR. Do is.muni zaevidováno na základě žádosti pana prof. Dobšáka.
N2  - Background We hypothesized that percutaneous coronary intervention (PCI) preceded by early treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abciximab alone (abciximab-facilitated PCI) would improve outcomes in patients with acute ST-segment elevation myocardial infarction, as compared with abciximab administered immediately before the procedure (primary PCI). Methods In this international, double-blind, placebo-controlled study, we randomly assigned patients with ST-segment elevation myocardial infarction who presented 6 hours or less after the onset of symptoms to receive combination-facilitated PCI, abciximab-facilitated PCI, or primary PCI. All patients received unfractionated heparin or enoxaparin before PCI and a 12-hour infusion of abciximab after PCI. The primary end point was the composite of death from all causes, ventricular fibrillation occurring more than 48 hours after randomization, cardiogenic shock, and congestive heart failure during the first 90 days after randomization. Results A total of 2452 patients were randomly assigned to a treatment group. Significantly more patients had early ST-segment resolution with combination-facilitated PCI (43.9%) than with abciximab-facilitated PCI (33.1%) or primary PCI (31.0%; P = 0.01 and P = 0.003, respectively). The primary end point occurred in 9.8%, 10.5%, and 10.7% of the patients in the combination-facilitated PCI group, abciximab-facilitated PCI group, and primary-PCI group, respectively (P = 0.55); 90-day mortality rates were 5.2%, 5.5%, and 4.5%, respectively (P = 0.49). Conclusions Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab alone significantly improved the clinical outcomes, as compared with abciximab given at the time of PCI, in patients with ST-segment elevation myocardial infarction.
ER  -

ELLIS, SG, M TENDERA, Belder MA DE, Boven AJ VAN, Petr WIDIMSKÝ, L JANSSENS, HR ANDERSEN, A BETRIU, S SAVONITTO, J ADAMUS, JZ PERUGA, M KOSMIDER, O KATZ, T NEUNTEUFL, J JORGOVA, M DOROBANTU, L GRINFELD, P ARMSTRONG, BR BRODIE, HC HERRMANN, G MONTALESCOT, FJ NEUMANN, MB EFFRON, ES BARNATHAN and EJ TOPOL. Facilitated PCI in patients with ST-elevation myocardial infarction. \textit{New England Journal of Medicine}. USA: MASSACHUSETTS MEDICAL SOC, 2008, vol.~358, No~21, p.~2205-2217. ISSN~0028-4793. Available from: https://dx.doi.org/10.1056/NEJMoa0706816.

Detailed Information on Publication Record